Streetbeat News

Revenues

GOOG

GOOGL

HUBS

HubSpot Inc (NYSE:HUBS) shares surged after reports that Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) is considering an acquisition offer. The news follows HubSpot's reported revenue increase and its anticipation of higher revenues in 2024. HubSpot's stock was briefly halted due to volatility but continued to rise after trading resumed.

Portfolio Pulse from Adam Eckert

April 04, 2024 | 2:09 pm

IZEA

IZEA Worldwide, Inc. (NASDAQ:IZEA) reported a 53% YoY increase in Q1 2024 Managed Services bookings, totaling $9.3 million, up from $6.1 million in Q1 2023. The growth is attributed to organic efforts and a record-setting sales pipeline. Additionally, the company saw a recovery in SaaS revenue, ending Q1 2024 with the highest number of SaaS customers ever. Bookings, which are not a direct indicator of revenue, are expected to be recognized over a seven to nine-month period.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 2:08 pm

DTSS

Datasea Inc. (DTSS) has entered into a sales agreement with Shenzhen Xiaoranfang Marketing Co., Ltd. for the sale of up to approximately $8.45 million of its acoustic high tech products. This partnership aims to boost Datasea's product sales both domestically and internationally, including on U.S. platforms like Amazon. The agreement covers the sale of Datasea's 'Hailijia' and 'Star Dream' series, which include air disinfection machines and sleep aids. The partnership is expected to be a key driver of Datasea's future revenue growth.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 2:02 pm

PSN

Seven analysts have recently updated their ratings on Parsons Corp (NYSE:PSN), showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target for PSN has been raised to $76.86, indicating a positive sentiment shift. Parsons Corp, a technology-driven solutions provider, has shown strong financial performance with a notable revenue growth rate of 35.46% and a net margin of 3.01%, although its ROE is below industry standards.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 2:01 pm

MCB

Metropolitan Bank Holding (NYSE:MCB) was analyzed by 4 analysts, all giving somewhat bullish ratings with no change over the past 3 months. The average 12-month price target is $56.5, down from $64.00, indicating a negative sentiment shift. The bank's financial performance shows a -9.53% revenue decline, but strong profitability with a 22.8% net margin and above-average ROE and ROA. Its debt management is prudent with a debt-to-equity ratio of 0.83.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 2:01 pm

CYRX

Five financial analysts have recently shared mixed evaluations of CryoPort (NASDAQ:CYRX), with ratings ranging from bullish to indifferent. Over the past three months, the sentiment has shifted, with the latest 30-day period seeing one bullish rating. Analysts have updated their 12-month price targets for CYRX, setting an average target of $18.4, up from $17.12, indicating a 7.48% increase. The company, a leader in temperature-controlled supply chain solutions for the life sciences industry, faces challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 2:00 pm

EBAY

11 analysts have recently shared their evaluations of eBay, showing a mix of bullish and bearish perspectives. The average 12-month price target for eBay is $50.55, reflecting a 6.65% increase from the previous target. Analysts from firms like Wells Fargo, Argus Research, and Barclays have adjusted their ratings and price targets, indicating a positive outlook on eBay's performance. eBay's financial overview highlights a revenue growth of 2.07%, a net margin of 28.26%, and an ROE of 11.78%, showcasing its strong market position and profitability.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 2:00 pm

STOK

Stoke Therapeutics (NASDAQ:STOK) has seen a diverse range of analyst opinions, with recent assessments showing a shift towards more bullish sentiments. The average 12-month price target for STOK has risen to $20.33, marking a significant increase from the previous $12.75. This change reflects analysts' positive outlook on the company's performance and market position. Stoke Therapeutics is focused on developing RNA-based medicines for severe diseases, with its leading compound, STK-001, targeting Dravet syndrome. Despite a recent revenue decline of -14.26%, the company's financial indicators such as net margin and ROE outperform industry averages, suggesting strong financial health and efficient cost management.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 2:00 pm

CELH

CELSIUS announced its plans to expand sales and distribution to France starting in Q4, aiming to increase its market presence and revenue.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 2:00 pm

TWLO

Twilio Inc (NYSE:TWLO) is facing significant challenges, including a 20% decline in stock year-to-date, leadership changes, and sluggish growth. The company's efforts to overhaul its business have not altered its core trajectory, leading to a bearish outlook. Technical indicators, including a looming Death Cross, reinforce this sentiment. Despite a slight buying pressure, the overall technical analysis suggests a downturn, with no strong evidence of a potential short squeeze.

Portfolio Pulse from Surbhi Jain

April 04, 2024 | 1:45 pm